Similar articles

• Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.

  Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM. Abramson JS, et al. Blood. 2019 Aug 15;134(7):606-613. doi: 10.1182/blood.2019001272. Epub 2019 Jun 11. Blood. 2019. PMID: 31186274 Clinical Trial.
• Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

  Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Younes A, et al. Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15. Lancet Oncol. 2013. PMID: 24239220 Clinical Trial.
• Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.

  Straus D, Collins G, Walewski J, Zinzani PL, Grigg A, Sureda A, Illes A, Kim TM, Alekseev S, Specht L, Buccheri V, Younes A, Connors J, Forero-Torres A, Fenton K, Gautam A, Purevjal I, Liu R, Gallamini A. Straus D, et al. Leuk Lymphoma. 2020 Dec;61(12):2931-2938. doi: 10.1080/10428194.2020.1791846. Epub 2020 Aug 25. Leuk Lymphoma. 2020. PMID: 32842815
• An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.

  Choi Y, Diefenbach CS. Choi Y, et al. Expert Rev Hematol. 2019 Oct;12(10):801-808. doi: 10.1080/17474086.2019.1658522. Epub 2019 Sep 5. Expert Rev Hematol. 2019. PMID: 31432732 Review.
• Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.

  Reid JH, Marini BL, Nachar VR, Brown AM, Devata S, Perissinotti AJ. Reid JH, et al. Crit Rev Oncol Hematol. 2020 Apr;148:102897. doi: 10.1016/j.critrevonc.2020.102897. Epub 2020 Feb 13. Crit Rev Oncol Hematol. 2020. PMID: 32109715 Review.